Literature DB >> 24722391

Variation in adherence to the treatment guidelines for Neisseria gonorrhoeae by clinical practice setting, California, 2009 to 2011.

Richard J Lechtenberg1, Michael C Samuel, Kyle T Bernstein, Maureen Lahiff, Nicole Olson, Heidi M Bauer.   

Abstract

BACKGROUND: Declining susceptibility of Neisseria gonorrhoeae to available antimicrobial agents has prompted repeated updates of the Centers for Disease Control and Prevention (CDC) treatment guidelines. The only regimen currently recommended as first-line treatment is dual therapy consisting of an intramuscular dose of ceftriaxone together with azithromycin or doxycycline. The objective of this analysis is to identify how adherence to the CDC guidelines varies by clinical practice setting.
METHODS: A geographically representative random sample of N. gonorrhoeae cases reported from 2009 to 2011 was analyzed. Weighted generalized linear models were fit to calculate cumulative incidence ratios for receipt of non-recommended treatment regimen in relation to clinical practice setting, adjusted for age, race, and whether or not the participant was a man who has sex with men.
RESULTS: Data from 3178 participants were available for analysis. Overall, 14.9% (weighted) of participants received non-recommended treatment. Among participants with gonorrhea identified by surveillance data as having received non-recommended treatment, the largest proportions were treated at private physicians' offices or health maintenance organizations (34.7% of participants receiving non-recommended treatment), family planning facilities (22.3%), and emergency departments/urgent care centers (12.8%).
CONCLUSIONS: Barriers to adherence to the CDC treatment guidelines for gonorrhea seem to be experienced in a variety of clinical practice settings. Despite only moderate rates of nonadherence, interventions targeting private physicians/health maintenance organizations and family planning facilities may produce the largest absolute reductions in guideline-discordant treatment.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24722391     DOI: 10.1097/OLQ.0000000000000113

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN: 0148-5717            Impact factor:   2.830


  5 in total

1.  Differences in Treatment of Chlamydia trachomatis by Ambulatory Care Setting.

Authors:  William S Pearson; Thomas L Gift; Jami S Leichliter; Wiley D Jenkins
Journal:  J Community Health       Date:  2015-12

2.  Plasmid-mediated resistance to tetracyclines among Neisseria gonorrhoeae strains isolated in Poland between 2012 and 2013.

Authors:  Beata Młynarczyk-Bonikowska; Marlena Kujawa; Magdalena Malejczyk; Grażyna Młynarczyk; Sławomir Majewski
Journal:  Postepy Dermatol Alergol       Date:  2016-12-02       Impact factor: 1.837

Review 3.  Multiresistant Neisseria gonorrhoeae: a new threat in second decade of the XXI century.

Authors:  Beata Młynarczyk-Bonikowska; Anna Majewska; Magdalena Malejczyk; Grażyna Młynarczyk; Sławomir Majewski
Journal:  Med Microbiol Immunol       Date:  2019-12-04       Impact factor: 3.402

4.  Adherence to CDC Recommendations for the Treatment of Uncomplicated Gonorrhea - STD Surveillance Network, United States, 2016.

Authors:  Emily J Weston; Kimberly Workowski; Elizabeth Torrone; Hillard Weinstock; Mark R Stenger
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2018-04-27       Impact factor: 17.586

5.  What are Canadian primary care physicians prescribing for the treatment of gonorrhea?

Authors:  S Ha; L Pogany; J Seto; J Wu; M Gale-Rowe
Journal:  Can Commun Dis Rep       Date:  2017-02-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.